BUDGET IMPACT of BROLUCIZUMAB in NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: West Virginia A US PAYER PERSPECTIVE BASED on MANUFACTURER and PRO RE NATA GUIDELINES Zasim Azhar Siddiqui, Trupti Dhumal, KiJin Jeun, Khalid M Kamal



Department of Pharmaceutical Systems and Policy, West Virginia University School of Pharmacy, Morgantown, WV, USA

Author Contact: Zasim Siddiqui; Email: zds0011@mix.wvu.edu | References available on request

ODS					
ATION 35.6% years = 1.20% t = 83.5% SHARE			 A total of 3,420 p nAMD were estimation Ranibizumab sho manufacturer reg Brolucizumab sho regimen (one eye 		
after launch = 4	%				
After Brolucizumab Launch			nousands	One-year Bud \$60,000 \$46,08 \$40,000	
Brolucizumab	After B	rolucizumab		\$20,000	
NA 25%		4% 24%	Costs		
17%	15%			ONE	
58%	57%			Brolucizumah coste	
DRUG COST				Prevalence of nAMD (95% CI	
Manufacturer	PRN	Cost / Unit		Proportion of patients on anti-\ Market s	
7.0	5.6	\$1,850	Net-	Both -budgetary impact (in tho	
12.0	4.7	\$ 1,950			
8.0	4.2	\$ 1,850	Pr	Prevalence of nAMD (95% CI 0. Brolucizumab costs (V	
12.0 oth eyes= \$ 155 DA labels. r Ranibizumab & Aflibercep	6.4 ot; CATT for Bev	\$73 vacizumab; HAWK and	Net-k	roportion of patients on anti-VE Market sha Both eg oudgetary impact (in thou	
Ionitoring Cos	t				
each visit = $$41$ = $$106$ both eves= $$211$				budget impact of treatment regimen AMD is warranted.	

RESULTS

patients (one eye: 2,855 and both eyes: 566) with imated to be on anti-VEGF treatment. nowed highest annual per-patient cost for the

egimen (one eye \$26,624; both eyes \$50,749).

howed the highest annual per-patients cost for the PRN ye \$11,636 ; both eyes \$21,149).

BASE CASE MODEL

